Compare Strategy Inc. (MSTR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Repligen Corporation Common Stock — how do they compare? Strategy Inc. trades at $140.91 (market cap $64.44B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Strategy Inc. is far larger — about 5.8× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 113 Days and Repligen Corporation Common Stock for 0 Days on average.
| MSTR | RGEN | |
|---|---|---|
Market Cap | $64.44B | $11.14B |
Volume | 12,273,653 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $301.91 | $194.57 |
52-Week Low | $82.31 | $102.87 |
Typical Hold Time | 113 Days | 0 Days |
Enterprise Value | $83.20B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR stock trades at $143.24, down 6.18% today, with technical indicators showing neutral momentum near key support at $142. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite negative profitability metrics including a -6,102.96% net income margin, analyst consensus remains bullish with 62% buy ratings and a $253.36 price target representing 77% upside potential from current levels.
The investment case hinges on analyst optimism despite fundamental challenges, with Citigroup recently doubling its price target to $240. Key risks include persistent negative earnings, high valuation multiples (P/S of 96.6), and substantial debt load of $7.19 billion. Cash flow trends show heavy reliance on financing activities to support operations and investments.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
